Abstract 3632
Background
Activation of the MAPK pathway via the BRAF V600 mutation has been observed in several tumors. This mutation is observed in a subset of pediatric brain tumors, including HGG and LGG for which limited therapeutic options are currently available. In a phase I/II clinical trial of pediatric patients (pts) with recurrent or refractory BRAF V600–mutant relapsed tumors, the BRAF inhibitor dabrafenib demonstrated its efficacy, including complete responses, in pediatric pts with HGG and LGG. As the combination of dabrafenib plus the MEK inhibitor trametinib has resulted in improved efficacy in multiple adult BRAF V600–mutant tumors, including melanoma and non-small cell lung cancer, this combination warrants further investigation in pediatric pts with gliomas bearing the same mutation.
Trial design
This global, open-label, phase II study (NCT02684058) will evaluate the anti-tumor activity of the combination of dabrafenib plus trametinib in 2 pediatric glioma cohorts recruiting from up to 70 sites across 17 countries. The single-arm BRAF V600–mutated HGG cohort of approximately 40 pts (aged ≥ 6 and < 18 y) with relapsed or refractory disease will be treated with dabrafenib twice daily (BID) plus trametinib once daily (QD) based on age and weight. The primary endpoint for this cohort is overall response rate (ORR) per investigator’s assessment according to Response Assessment in Neuro-Oncology (RANO) criteria. The BRAF V600–mutated LGG cohort of approximately 102 chemotherapy-naive pts (aged ≥ 6 and < 18 y) with unresectable disease will be randomized 2:1 to receive either dabrafenib (BID) plus trametinib (QD) or carboplatin plus vincristine. The primary endpoint for the LGG cohort is ORR per independent assessment according to RANO criteria. Pt crossover from the chemotherapy arm to the experimental arm will be allowed after independent confirmation of radiologic disease progression. Key secondary endpoints for both cohorts include duration of response, progression-free survival, time to response, clinical benefit rate, overall survival, and safety/tolerability.
Clinical trial identification
NCT02684058.
Legal entity responsible for the study
Novartis Pharmaceuticals Corporation.
Funding
Novartis Pharmaceuticals Corporation.
Editorial Acknowledgement
Medical writing assistance was provided by William Fazzone, PhD (ArticulateScience LLC), funded by Novartis Pharmaceuticals Corporation.
Disclosure
D. Hargrave: Consultancy: Novartis. O. Witt: Membership on board of directors or advisory committees: Novartis; Study committee on selumetinib trial: AzstraZeneca. K. Cohen: Research Funding: Novartis; Membership on board of directors or advisory committees: Novartis. T.W. Laetsch: Consultancy: Novartis, Loxo Oncology, Bayer; Research funding: Pfizer. A. Lassaletta: Consultancy: Shire, Clinigen. C. Kramm: Research funding: Novartis, Eisai, Boehringer Ingelheim, Merck. C. Reitmann, M.W. Russo: Employment: Novartis; E. Bouffet: Research funding to institution: Roche, Bristol-Myers Squibb.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract